![Nicholas Haft](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nicholas Haft
Fondatore presso Delix Therapeutics, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Susan Graf | F | 52 | 3 anni | |
Chris Shumway | M | 58 | 4 anni | |
David E. Olson | M | - |
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | - |
Mark Rus | M | - |
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 3 anni |
Nick Haft | M | - |
Arcos Ventures SPV LLC
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 10 anni |
Lance Thibault | M | 58 | 1 anni | |
Paul Conley | M | 56 |
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 6 anni |
Vasudev Bailey | M | - |
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 3 anni |
Matthew Nelson | M | - | 3 anni | |
Matthew Blischak | M | - | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Marc Blaustein | M | 61 | 2 anni | |
Mark Smith | M | 37 | 6 anni | |
Andrew Noh | M | - | 4 anni | |
Gregory Perry | M | 63 | 4 anni | |
Joseph Vittiglio | M | 52 | 2 anni | |
Samuel Hamood | M | 56 | - | |
Zain Kassam | M | 42 | 4 anni | |
Anne Marie Conway | F | - | - | |
Alka Batycky | M | 54 | 1 anni | |
Debra Silberg | M | - | - | |
Chris Weidenmaier | M | - | - | |
David Rhodes | M | - | 3 anni | |
David Pugatch | M | - | 2 anni | |
Bryan Gillis | M | - | 1 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 24 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Nicholas Haft
- Contatti personali